期刊文献+

人外周血γδT细胞对裸鼠人肺癌移植瘤治疗作用的研究

Therapeutic effect of human peripheral γδT cells on human lung cancer xenograft in nude mice
原文传递
导出
摘要 目的:探讨人外周血γδT细胞对已建立肺癌裸鼠的免疫治疗作用。方法:用人肺癌细胞株A549接种BALB/c裸鼠皮下,建立肺癌裸鼠模型。从健康人外周血中提取γδT淋巴细胞,体外特异性扩增γδT细胞。将已建立肺癌的裸鼠随机分为两组,对照组用RPMI1640培养液,治疗组用γδT细胞分别注入裸鼠腹腔内,观察种植瘤裸鼠生存时间及肿瘤体积,并同时检测肿瘤细胞c-jun的表达。结果:裸鼠接种5×106肺癌细胞后第14天,在接种部位均有肿瘤形成,直径平均为2 mm。在首次治疗后49 d时,对照组、治疗组平均肿瘤体积分别为(0.97±0.32)和(0.46±0.25)cm3,差异有统计学意义,P<0.05。至75 d时,对照组种植瘤裸鼠全部死亡,治疗组生存天数较对照组差异有统计学意义,P<0.05。结论:人外周血γδT细胞对肺癌裸鼠种植瘤具有显著的抑瘤作用,为肺癌免疫治疗提供了一种新的治疗方法。 OBJECTIVE:To explore the immunotherapy effect of peripheral γδT cells in lung cancer nude mice model.METHODS: Xenografted animal model of human lung cancer was established by innoculating human lung cancer A549 cells into BALB/c nude mice subcutaneously.And then the mice were divided into two groups randomly,γδ T cells and control group.γδT cells or RPMI-1640 were respectively injected into abdominal cavity of mice,Tumor volume and he survival rate of two groups were compared.The expression of c-jun was tested on tumor cell.RESULTS: The nude mice inoculated with 5×106 lung cancer cells,after fourteen days in the inoculation site a diameter of 2-3 mm tumor was formed.In the first 49 days after treatment determined two group tumor average size were(0.97±0.32) cm^3 and(0.46±0.25) cm^3 respectively,the treatment groups with a very significant difference compared with the control group in the tumor size(P〈0.05).After 75 days,all the mice in control group died,The survival time of treat ment group was longer than that of control group(P〈0.05).CONCLUSION: Human peripheral γδT cells can inhibit the growth of human lung cancer xenograft in nude mice effectively.
出处 《中华肿瘤防治杂志》 CAS 2009年第22期1731-1734,共4页 Chinese Journal of Cancer Prevention and Treatment
关键词 肺肿瘤 疾病模型 动物 ΓΔT细胞 小鼠 肿瘤移植 免疫疗法 lung neoplasms disease models animal γδ T cells mice nude neoplasm transplantation immunotherapy
  • 相关文献

参考文献12

  • 1刘军权,陈复兴,朱斌,张颂,张娟,陶征中,李佚.阿司匹林对人γδT细胞杀伤消化系统肿瘤细胞的影响[J].细胞与分子免疫学杂志,2008,24(10):966-968. 被引量:7
  • 2Guo B L, Liu Z, Aldrich W A, et al. Innate anti-breast cancer immunity of apopto sisresistant human γδ-T cells [J]. Breast Cancer Res Treat,2005,93(2):169-175.
  • 3Sato K, Kimura S, Segawa H, et al. Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy[J]. Int J Cancer, 2005,116(1) : 94-99.
  • 4许顺 赵惠儒 胡永校 等.CD3^+TCRTγδ^+T淋巴细胞亚群在肺癌患者外周血中表达及临床意义的研究.中国肿瘤生物治疗杂志,1997,4(3):238-239.
  • 5王春利,张少云,马炎炎,张素英,郭石平,张双平.肺癌患者外周血免疫细胞毒细胞的检测[J].肿瘤研究与临床,2006,18(1):35-36. 被引量:5
  • 6高岱清,刘淑贞,赵鹏,徐珞.恶性肿瘤术后DC联合CIK治疗的临床观察[J].中华肿瘤防治杂志,2009,16(3):222-225. 被引量:13
  • 7王小路,何维,张连山.鼻咽癌患者γδT细胞体外扩增及Vδ亚型表达的研究[J].解放军医学杂志,2006,31(2):135-137. 被引量:6
  • 8Kabelitz D, Wesch D, Pitters E, et al. Characterization of tumor reactivity of human Vγ9Vδ2 γδ T cells in vitro and in SCID mice in vivo [J]. J Immunol,2004,173(11): 6767-6776.
  • 9Scotet E, Martinez L O, Grant E, et al. Tumor recognition fol lowing Vγ9Vδ2 T cell receptor interactions with a surface F1 ATPase-related structure and apolipoprotein A-Iγδ. Immunity 2005, 22(1) :71-80.
  • 10Kong Y, Cao W, Xi X, et al. The NKG2D ligand ULBP4 binds to TCRgamma9/delta2 and induces cytotoxicity to tumor ceils through both TCRgammadelta and NKG2D[J]. Blood, 2009, 114(2): 310-317.

二级参考文献38

  • 1谭国林,游孟高.鼻咽癌外周血淋巴细胞亚群白细胞介素2产生及受体表达[J].中华耳鼻咽喉科杂志,1993,28(3):167-169. 被引量:2
  • 2龚选举,李妹,王岩,袁素,符志龙,董玉英,陈春吉.肿瘤浸润树突状细胞在肺癌组织中浸润的研究[J].中华实验外科杂志,2005,22(8):935-935. 被引量:4
  • 3许晓群,陈雪梅,张彩,游力,赵昌盛,王郡甫,张建华.人NKG2D的基因克隆及其在CHO细胞中的表达[J].细胞与分子免疫学杂志,2006,22(4):447-449. 被引量:4
  • 4罗小玲,谢裕安,匡志鹏,吴继宁,梁安民.肝癌树突状细胞瘤苗诱导抗肿瘤作用的研究[J].中华肿瘤防治杂志,2007,14(11):805-808. 被引量:6
  • 5巩新建,刘军权,陈复兴,李玺,费素娟,唐涛.舒林酸对人γδT细胞的作用研究[J].南京医科大学学报(自然科学版),2007,27(7):666-670. 被引量:4
  • 6Leonard G D, Reilly E M. Post-operative chemotherapy improves disease free survival, but not overall survival in people with oeso phageal squamous cell carcinoma[J]. Cancer Treat Rev, 2004, 30(5):473-477.
  • 7Armanious M, Xu R, Forastiere A A, et al. Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase Ⅱ trial (E8296) of the Eastern Cooperative Oncology Group[J]. J Clin Oncol, 2004,22 (22) : 4495-4499.
  • 8Mushiake H, Tsunoda T, Nukatsuka M, et al. Dendritic cells might be one of key factors for eliciting antitumor effect by chemoimmuno therapy in vivo[J]. Cancer Immunol, 2005, 54(2):120-128.
  • 9Koido S, Hara E, Homma S, et al. Dendritic/tumor fusion cell-based vaccination against cancer[J]. Arch Immunol Ther Exp (Warsz), 2007, 55(5) :281-287.
  • 10Whiteside T L. Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor[J]. Curr Cancer Drug Targets, 2007,7(7) :633-642.

共引文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部